Rakuten Aspyrian Pipeline
Rakuten Aspyrian’s lead investigational product is ASP-1929. ASP-1929 is an antibody-drug conjugate of cetuximab and IRDye 700DX®. ASP-1929 targets epidermal growth factor (EGFR), which is expressed in multiple types of solid tumors, including head and neck squamous cell carcinomas, esophageal cancer, lung cancer, colorectal cancer, pancreatic cancer, and other cancers. After the antibody binds to the tumor, ASP-1929 is locally activated with red light using a proprietary investigational laser and fiber optics.
The interim results of the Phase 1/2 trial (RM-1929/101) showed an improvement in the clinically meaningful endpoint of overall response rate, and potential improvements in progression free survival and overall survival when compared to the historical data for the standard of care treatments currently available to this patient population.
Rakuten Aspyrian is currently sponsoring a global Phase 3 multicenter clinical trial for ASP-1929, called LUZERA-301, to evaluate the efficacy and safety of ASP-1929 in patients with recurrent head and neck cancer, as well as additional Phase 2 studies to treat other cancer types.
The graphic below displays the ongoing and planned clinical development programs and preclinical assets.